Role of Primary Care Physician in Management of Generalized Anxiety Disorder

Faisal Suliman Algaows a#*, Hajar Saleh Alnajdi b, Khalifah Sulaiman Alsuqayh c, Basel Ali S. Alqahtani d, Arishi, M. Khaled Yahya e, N. Alomrani, Nawaf Farag f, Sarh Sami Abdulghani g, Farah Najeh ALShammari h, Khalid Ali Alsaykhan i, Hozan Mohammed Ali j, Sakinah Jawad Al Kuwaiti k, S. Alsanna, Haytham Bager l, E. Alhzami, Essa Ibrahim m, Abdulelah Abdulrhman Najmi n and Yassir Mohammed Darwish o

a King Abdulaziz Medical City, National Guard, Iskan PHC, Saudi Arabia.
b Vision College of Medicine, Vision Colleges, Riyadh, Saudi Arabia.
c Maternity and Children Hospital Buraydah, Saudi Arabia.
d GP - Primary Health Care - Asser- Ahad Rofaidah, Saudi Arabia.
e Primary Health Care Asser, Abha, Saudi Arabia.
f University of Tabuk, Saudi Arabia.
g Ibn Sina College, Saudi Arabia.
h Aljouf University, Saudi Arabia.
i Qassim University, Saudi Arabia.
j University of Sulaimani, Iraq.
k King Fahad Hospital in Hofuf, Saudi Arabia.
l Prince Sultan Hospital Mulaijah, Saudi Arabia.
m Al Qunfudah General Hospital, Saudi Arabia.
n Medical College of Jazan University, Saudi Arabia.
o Heraa General Hospital, Saudi Arabia.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i60B34783

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/81545

Received 17 October 2021
Accepted 20 December 2021
Published 23 December 2021
ABSTRACT

Individual survival would be impossible without anxiety, which is a natural and important emotion. Anxiety is considered a disease that requires treatment when it occurs in the absence of a threat, or in a disproportionate proportion to a threat, as well as when it prevents the affected individual from leading a normal life. Generalized Anxiety Disorder (GAD) is a widespread mental disorder characterized by excessive and difficult-to-control anxiety and concerns, as well as a variety of psychological and physical symptoms. Patients with GAD frequently visit primary care, and it is widely acknowledged that the majority of patients should be treated in this environment. Clinical practice guidelines advocate pharmacological (e.g., SSRIs and venlafaxine) or cognitive behavior therapy as first-line therapies for GAD. There are several proposed etiological explanations for GAD, including Freud's psychodynamic theory, Stack's interpersonal theory, and the Stress Diathesis Model. The exact pathophysiological process of the disease is not fully understood. Patients with GAD frequently visit primary care, and it is widely acknowledged that the majority of patients should be treated in this environment. Clinical practice guidelines advocate pharmacological (e.g., SSRIs and venlafaxine) or cognitive behavior therapy as first-line therapies for GAD. In this article, we'll be discussing GAD epidemiology, etiology, evaluation, and treatment.

Keywords: Behavioural therapy; anxiety disorder; pathophysiological; mental disorder.

1. INTRODUCTION

Generalized Anxiety Disorder (GAD) is a widespread mental disorder characterized by excessive and difficult-to-control anxiety and concerns, as well as a variety of psychological and physical symptoms. GAD frequently has a long-term course, with a lifetime prevalence rate of around 6% for DSM-IV criteria. People with GAD have major problems at work, in their social and familial lives, and in their health-related quality of life. There is also mounting evidence of GAD's economic impact in terms of missed job productivity and medical expenditures resulting from excessive use of medical services. GAD is strongly linked to concomitant mental diseases, the most common of which is major depressive disorder, as well as comorbid physical sickness [1–7].

GAD has also been linked to medical conditions such as heart disease, GI issues, and chronic pain. Such connections are clinically significant because people with mental or medical comorbidities have a longer clinical course and worse outcomes than people with GAD alone. The presence of pain has been found in the PCAP to have a negative impact on the progression of anxiety disorders. In a subset of GAD patients, the occurrence of back pain was linked to a lower risk of remission. Patients with comorbidities have a larger therapeutic challenge, necessitating the use of innovative medicines or a mix of treatments, such as polypharmacy with pharmaceuticals from other classes or extra nonpharmacologic techniques [8].

Individual survival would be impossible without anxiety, which is a natural and important emotion. Anxiety disorders, as well as most other kinds of mental disease, can cause pathologically heightened anxiety. Anxiety can also be a symptom of potential threat in cases of somatic disorders. A complete psychological and somatic assessment is required for any patient presenting with pathologically heightened anxiety in order to rule out an underlying lung, cardiovascular, neurological, or endocrine condition. Anxiety reactions are important indicators of a possible threat to homeostasis; anxiety is considered a disease that requires treatment when it occurs in the absence of a threat, or in a disproportionate proportion to a threat, as well as when it prevents the affected individual from leading a normal life [9].

Patients with GAD frequently visit primary care, and it is widely acknowledged that the majority of patients should be treated in this environment. Clinical practice guidelines advocate pharmacological (e.g., SSRIs and venlafaxine) or cognitive behavior therapy as first-line therapies for GAD, with long-term therapy being necessary to avoid recurrence. In epidemiological surveys in Canada, the United States, Spain, and Australia, treatment adequacy rates for patients with GAD ranged from 24.6 percent to 42.5 percent, and from 44.2 percent to 43.8 percent in clinical trials in the United States, and 49.5
percent in a primary care sample in the Netherlands. While GAD has certain similarities to other anxiety disorders, we cannot assume that the determinants of potentially effective psychological and pharmaceutical therapies are the same. For instance, investigation has also shown that perceptions of treatment need, assistance behavior, care delivery, and recognition and treatment of mental disorders by healthcare professionals differ across common mental disorders, potentially affecting the likelihood of receiving potentially adequate treatments [1,10–14].

2. ETIOLOGY AND PATHOPHYSIOLOGY

Several etiological explanations for GAD have been proposed, including Freud’s psychoanalytic theory, which states that anxiety is caused by intrapsychic conflict between the id and superego; Stack’s interpersonal theory, which states that anxiety is caused by unmet interpersonal needs; the Stress Diathesis Model; personality factors; and neurobiological factors [15]. The following factors may have a role in the etiology:

- Stress
- Comorbidities include medical conditions such as diabetes and other comorbidities such as depression.
- Generalized anxiety disorder (GAD) among first-degree relatives (25 percent)
- Factors in the environment, such as child abuse
- Abuse of drugs and alcohol [16]

The specific process isn’t well understood. Stranger anxiety appears between the ages of seven and nine months. The body’s response to stress appears to be influenced by noradrenergic, serotonergic, and other neurotransmitter systems. The serotonin and noradrenergic systems are two major pathways that have a role in anxiety. Many believe that decreased serotonin system activity and increased noradrenergic system activity are responsible for its development. As a result, serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) are the first-line treatments for it [16].

3. EPIDEMIOLOGY

As shown in a 6-month prevalence estimates accepted for publication by World Health Organization (WHO) research in 14 countries, including the U.S, more than 8% of patients visiting a general practitioner had GAD. The lifetime prevalence of the illness is estimated to be around 5%–6% using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, though the European Study of the Epidemiology of Mental Disorders (ESEMeD) provides a lower estimate of 2.8 percent. While the incidence estimates in the ESEMeD questionnaires are typically comparable to other studies, it’s been suggested that several incidence rate may be underestimated due to ESEMeD research methods, such as the way analytic interviews were conducted. GAD affects twice as many women as men and is more common in middle age, with incidence rates starting to rise after the ages of 35 for women and 45 for men. GAD is thought to be common among the elderly, with various estimates as 7.3% [8,17–22].

Delaying therapy can lead to long-term psychosocial and professional dysfunction, as well as an increased risk of suicide, medical and mental comorbidities, and a significant financial load on the healthcare system. Recurrence of symptoms is more probable without early treatment, and remission may be more difficult to achieve. In the United States, the yearly cost of GAD disability is projected to be $42 billion [15].

4. EVALUATION

Excessive anxiety can cause headaches, dizziness, irritability, muscle tension, heart palpitations, chest pain, tachycardia, sweating, and shortness of breath. While anxiety is a universal phenomena that can encourage people to finish work and escape harmful circumstances through "fight or flight,"it can also cause decreased concentration, insomnia, daytime fatigue, distorted perceptions of reality, increased performance errors, headaches, dizziness, irritability, muscle tension, heart palpitations, and anxiety. disorders. According to the DSM-IV-TR, these symptoms coexist with many physical diseases such as agoraphobia, panic disorder, specific and social phobias, obsessive-compulsive disorder (OCD), posttraumatic stress disorder (PTSD), acute distress disorder, and GAD, the last being the most common anxiety disorder encountered in primary care [15].

The key diagnostic criteria for GAD are excessive anxiety and concern, as well as at least three symptoms from a list of six
Fear and worry are common symptoms of all anxiety disorders. Worry is a sense of anxiety, a sense of discomfort in response to an unknown threat, whereas fear is a response to a recognized threat. The fundamental symptoms of GAD include dread and worry, as well as poor concentration, disrupted sleep, irritability, muscular tension, exhaustion, and sensations of arousal. Patients with GAD, according to the DSM-IV-TR, have these symptoms more days than not for at least 6 months [15].

5. MANAGEMENT

The plan for treatment includes managing the following: The severity of the condition, the presence of concurrent medical illness, complications such as substance abuse or the risk of suicide, the outcomes of any previous treatments, cost issues, the availability of treatment in a given area, and patient preferences should all be considered in the treatment plan for GAD. The treatment's overall goals are fourfold: (1) to reduce GAD's core symptoms (both psychic and somatic), including sleep restoration; (2) to improve patient function and quality of life; (3) to treat comorbid disorders, both those present at the time of diagnosis and those that develop over time; and (4) to continue treatment long enough to produce remission and, where possible, prevent relapse.

Pharmacotherapy, psychotherapy, or a combination of both are the most common treatment options for GAD. Due to the persistent and severe nature of GAD, some people may not respond completely to first-line therapy. As a result, patients may require a series of therapies or the use of combination therapies [16].

Cognitive behavioural therapy (CBT) is the form of psychotherapy with the most evidence and the highest degree of recommendation for all sorts of anxiety disorders. The therapeutic effectiveness of psychodynamic therapy, such as in social phobia, has been proven in preliminary randomised controlled studies. Despite this, psychodynamic therapy is given evidence level IIa in the current German guidelines due to the incomplete state of data from clinical trials, as well as the recommendation that it be used if cognitive behavioural therapy has been ineffective or is unavailable, or if an informed patient expresses a preference for it. The specifics of cognitive behavioural therapy differ based on the anxiety condition being treated, but the patient must have the experience that his or her situationally produced fear is unjustified and the situation is truly safe. This is best accomplished by exposure under the supervision of a therapist, during which the patient must become accustomed to the anxiety reaction, therefore refuting the primary fear that underpins it. Virtual reality exposure is becoming more common in cognitive-behavioral therapy methods [9,23–26].

The selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) groups of medications are first-line treatments, with response rates ranging from 30% to 50%. This class of drugs includes escitalopram (Lexapro), duloxetine (Cymbalta), venlafaxine (Effexor XR), and paroxetine (Paxil, Pexeva). In one investigation, children with anxiety problems improved in 81 percent of instances were given a combination of sertraline hydrochloride and CBT [16]. Some individuals, particularly those with accompanying behavioural difficulties, may benefit from antipsychotics.

In clinical practise, a recurrent question is how long medication therapy should be continued to avoid recurrence. Although response rates are typically high (about 80%), premature withdrawal of therapy is linked to significant recurrence rates. For example, 15–50% of people with panic disorder relapse within 6–12 months of stopping tricyclic antidepressants, SSRIs, or venlafaxine. As a result, it is suggested that SSRI or SNRI maintenance medication be continued for at least 6–12 months following the end of the acute
period, at the effective last dose achieved. Any attempt to stop taking medicine should be done gradually, such as over a period of 12 weeks if you’ve been on it for 40 weeks [9].

Benzodiazepines: Long-acting medicines such as diazepam and clonazepam are examples. When a quick decrease in symptoms is sought or a short-term therapy is required, these medicines are utilised. Benzodiazepines are more likely to help cooperative and compliant people who are aware that their symptoms have a psychological basis. Due to the risk of overuse and dependency, patients with a history of drinking or drug addiction are not suitable candidates for this therapy [16].

Buspirone is not a benzodiazepine and does not create addiction. It also has a lower sedative effect than benzodiazepines and does not cause tolerance at therapeutic levels. The therapeutic lag in effectiveness of this drug is two to three weeks, which limits its usage.

To see if a medicine helps, gradually raise the dose and keep it up for at least four weeks. After the symptoms have been controlled, the medications must be continued for at least 12 months before being gradually tapered off. Patients must be continuously monitored because all drugs have side effects such as weight gain, hyperlipidemia, and diabetes [16]. Recovery involves not just symptomatic relief as well as the return of patients to their peak functional ability, including the return to work, family, social, and action roles. In some lifelong cases of GAD, however, recovery can result in a level of well-being far superior to the premorbid baseline. Patients suffering from GAD are more likely to demand sleep aid, which can have a significant impact on quality of life and work performance. While immediate symptom relief is beneficial, it is more important to remind patients that they must adhere to their therapy in order to reap the most benefits and long-term improvement in their disease. It is possible that remission will take 4-6 months after beginning therapy [27].

6. CONCLUSION

Generalized Anxiety Disorder (GAD) is one of the important disorders presented at the primary care. Anxiety is important reaction for human survival, however when it’s pathological it causes serious impact on patient's health and quality of life. Most of guideline agrees on 2 methods of treatment one of which is cognitive behavior therapy and the other being pharmacological drugs such as SSRI, or benzodiazepines, or combination between non-pharmacological and pharmacological treatments. treatment’s overall goals are (1) to reduce GAD’s core symptoms (2) to improve patient function and quality of life; (3) to treat comorbid disorders (4) and to prevent relapse.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT AND ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. François Normand-Lauzière, Isabelle Raymond, Mireille Luc, Marie-Michèle Tanguay-Bernard, Arnaud Duhoux, Christian Bocti, Louise Fournier. Generalized Anxiety Disorder in Primary Care: Mental Health Services Use and Treatment Adequacy. BMC Fam Pract. 2015;16(146).
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
3. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet. 2006;368(9553):2156–66.
4. Wittchen HU, Beesdo K, Bittner A, Goodwin RD. Depressive episodes—evidence for a causal role of primary anxiety disorders? Eur Psychiatry. 2003;18(8):384–93.
5. Yonkers KA, Dyck IR, Warshaw M, Keller MB. Factors predicting the clinical course of generalised anxiety
disorder. Br J Psychiatry. 2000;176:544–9.

6. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001;62 Suppl 11:53–8.

7. Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: A 12-year prospective study. Am J Psychiatry. 2005;162(6):1179–87.

8. Wittchen HU, Hoyer J. Generalized anxiety disorder: nature and course. J Clin Psychiatry. 2001;62(suppl 11):15–19.

9. Ströhle A, Gensichen J, Domschke K. The Diagnosis and Treatment of Anxiety Disorders. Dtsch Arztebl Int. 2018 Sep 14;115(37):611-620. DOI: 10.3238/arztebl.2018.0611 PMID: 30282583; PMCID: PMC6206399.

10. Fernandez A, Haro JM, Codony M, Vilagut G, Martinez-Alonso M, Autonell J, et al. Treatment adequacy of anxiety and depressive disorders: primary versus specialised care in Spain. J Affect Disord. 2006;96(1–2):9–20.

11. Wang PS, Berglund P, Kessler RC. Recent care of common mental disorders in the United States: Prevalence and conformance with evidence-based recommendations. J Gen Intern Med. 2000;15(5):284–92.

12. Wang PS, Lane M, Olsson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):629–40.

13. Stein MB, Roy-Byrne PP, Craske MG, Campbell-Sills L, Lang AJ, Golinelli D, et al. Quality of and patient satisfaction with primary health care for anxiety disorders. J Clin Psychiatry. 2011;72(7):970–6.

14. Stein MB, Sherbourne CD, Craske MG, Means-Christensen A, Bystritsky A, Katon W, et al. Quality of care for primary care patients with anxiety disorders. Am J Psychiatry. 2004;161(12):2230–7.

15. Posmontier Bobbie, Breiter Dorit. Managing Generalized Anxiety Disorder in Primary Care. The Journal for Nurse Practitioners. 2012;8:268-274.

16. Munir S, Takov V. Generalized Anxiety Disorder. [Updated 2021 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Available:https://www.ncbi.nlm.nih.gov/books/NCBI441870/

17. Üstün TB, Sartorius N. Mental Illness in General Health Care: An International Study. Chichester, United Kingdom: Wiley. 1995;323–335.

18. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.

19. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:21–27.

20. Kessler RC. The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective. J Clin Psychiatry. 2007;68(suppl 2):10–19.

21. Beekman AT, Bremmer MA, Deeg DJ, et al. Anxiety disorders in later life: A report from the Longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry. 1998;13(10):717–726.

22. Davidson JR, Feltner DE, Dugar A. Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs. Prim Care Companion J Clin Psychiatry. 2010;12(2):PCC.09r00772 PMID: 20694114; PMCID: PMC2911006.

23. Andelow B, Wittink J, Alpers GW, et al. Deutsche S3-Leitlinie Behandlung von Angststörungen. Available:www.awmf.org/uploads/tx_szleitlinien/051-028L_S3_Angstst%C3%B6runge_2014-05_2.pdf

24. Leichsenring F, Salzer S, Beutel ME, et al. Psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: A multicenter randomized controlled trial. Am J Psychiatry. 2013;170:759–767.

25. Gloster AT, Wittchen HU, Einsle F, et al. Psychological treatment for panic disorder with agoraphobia: a randomized controlled
trial to examine the role of therapist-guided exposure in situ in CBT. J Consult Clin Psychol. 2011;79:406–420.

26. Diemer J, Mühlberger A, Pauli P, Zwanzger P. Virtual reality exposure in anxiety disorders: Impact on psychophysiological reactivity. World J Biol Psychiatry. 2014;15:427–442.

27. Jonathan R, Davidson T, Douglas E Feltner, Ashish Dugar. Management of Generalized Anxiety Disorder in Primary Care: Identifying the Challenges and Unmet Needs. Available:https://www.psychiatrist.com/pcc/medical/primary-care/management-generalized-anxiety-disorder-primary-care/